Combined Treatment for Alcohol-Dependent Individuals With PTSD



Status:Completed
Conditions:Psychiatric
Therapuetic Areas:Psychiatry / Psychology
Healthy:No
Age Range:18 - 65
Updated:4/17/2018
Start Date:May 2006
End Date:July 2013

Use our guide to learn which trials are right for you!

This treatment intervention trial is designed for men and women with either alcohol misuse
(e.g. hazardous or binge drinking) or alcohol use disorders (alcohol abuse or dependence) and
comorbid PTSD. Participants will be randomly assigned to one of two treatments (a cognitive
behavioral treatment intervention called "Seeking Safety" + Medication ("Zoloft") or Seeking
Safety + placebo) and will be evaluated at baseline, at completion of the treatment (12
sessions over 12 weeks), and again at 6 months and 12 months post-treatment.

The impetus for the current study is to contribute to the development of effective treatments
targeted for men and women with either alcohol misuse (e.g., hazardous or binge drinking) or
alcohol use disorders (e.g. alcohol abuse or alcohol dependence) and comorbid PTSD. Research
findings have shown that these individuals have poorer treatment outcomes and show more
severe symptoms than treatment seeking alcohol-misusing or alcohol dependent participants
without PTSD. The aim of this study is to replicate and expand on 1) pilot studies
demonstrating the effectiveness of a manualized cognitive-behavioral treatment specifically
designed for individuals with comorbid substance use disorders and PTSD, "Seeking Safety" 2)
preliminary results on the effectiveness of the antidepressant sertraline ("Zoloft") for a
dually diagnosed population and 3) the examination of the effectiveness of these
interventions over either treatment alone. We are comparing "Seeking Safety" alone to
"Seeking Safety" in combination with the antidepressant medication sertraline ("Zoloft") in
terms of their effectiveness in reducing alcohol use and PTSD symptoms. Participants will be
randomly assigned to one of two treatments (Seeking Safety + Med or Seeking Safety + placebo)
and will be evaluated at baseline, at completion of the treatment (12 sessions over 12
weeks), and again at 6 months and 12 months post-treatment. Secondary aims of the study
include exploring potential differences between alcoholic subtypes on treatment outcomes;
impact of combined treatment on treatment participation and global psychiatric symptoms;
differences in the time course and order of changes in alcohol and drug use and PTSD symptoms
by condition.

Inclusion Criteria:

1. Males and females who are a minimum of 18 years and maximum of 65 years.

2. Participants meet Diagnostic and Statistical Manual Diploma in Social Medicine IV
(DSM-IV) criteria for current alcohol misuse, abuse or dependence.

3. Participants must have current alcohol use over past 90 days defined by more than or
equal to 2 heavy drinking days or more than or equal to 14 drinks over 30 consecutive
days or abstinence less than or equal to 21 consecutive days.

4. Participants meet criteria for full or subthreshold PTSD. Subthreshold PTSD criteria
differs from full PTSD in that the individual meets cluster C (numbing) OR cluster D
(hyperarousal) whereas full PTSD requires that the individual meets both cluster C and
D.

5. Participants demonstrate no gross organic mental syndrome.

6. Participants are capable of giving informed consent and capable of complying with
study procedures.

7. Participants speak English.

Exclusion Criteria:

1. Individuals who are at significant risk for suicide based on their current mental
state or history.

2. Participants with other current Axis I psychiatric disorders that, in the
investigators' judgment, are unstable and would be disrupted by study medications.
Current diagnosis of Bipolar I and psychotic disorders are exclusionary.

3. Participants who are currently severely depressed.

4. Participants with a history of psychosis or mania.

5. Participants with organic mental syndrome.

6. Participants physiologically dependent on any substance other than alcohol (excluding
nicotine or caffeine or medically stable and managed methadone).

7. Participants with comorbid substance abuse disorder who require detoxification
treatment.

8. Participants with unstable or significant physical disorders (e.g., uncontrolled
hypertension, poorly-controlled diabetes, alanine aminotransferase/aspartate
aminotransaminase (AST/ALT) three times the upper limit of normal) that would increase
the risk of study participation.

9. Participants with a known history of seizures (not related to alcohol withdrawal).

10. Participants with moderate to severe alcohol withdrawal that would require
pharmacological intervention.

11. Participants currently taking prescribed psychotropic medication that is
contraindicated for use with sertraline (e.g. antidepressant medications except for
mirtazapine or trazodone when used for the treatment of insomnia ) and/or psychotropic
medications where the participant has not achieved a stabilized regimen. Participants
that are stable on medications that are not contraindicated with the use of sertraline
(e.g., Methadone or Adderall) will not be excluded.

12. A history of an allergic reaction to sertraline.

13. Women who are currently pregnant or are trying to get pregnant or are nursing or are
pre-menopausal and sexually active but not using effective birth control.

14. Participants refusing to be audio or videotaped.
We found this trial at
1
site
?
mi
from
New York, NY
Click here to add this to my saved trials